CAR-T Archives

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Jul 2021

Microbiome Medicines Could Power Up CAR-T Cell Therapies

The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may help CAR-T cell therapies penetrate and kill solid tumors. A recent study conducted by researchers at Philipps-University Marburg, University Hospital Würzburg, and the Leeds-based company 4D Pharma showed that metabolites produced by the gut bacteria […]

July 28, 2021 - 5 minutesmins - By Mark Zipkin

Best in Biotech 30 Jun 2021

Scotland’s Top 10 Biotech Companies to Watch Out For

Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial biotech. Let’s pick up the bagpipes as we tour the top 10 biotech companies in Scotland. Scotland is the UK’s second-most populous country, boasting picturesque scenery, a rich history, and a strong focus on sustainability. There is a diverse range […]

June 30, 2021 - 11 minutesmins - By Jonathan Smith

Reports 11 Nov 2020

Navigating the Immunotherapy Maze

Today, the global immunotherapy drugs market is valued at €139B ($163B) and is estimated to reach a staggering value of €149.3B ($174.6B) by 2025. Without a doubt, it is a flourishing field with new research emerging as you read. Discover now how antibodies, T cells, and exosomes are changing the immunotherapy field! While antibodies have […]

November 11, 2020 - 2 minutesmins - By Larissa Warneck-Silvestrin

Interview 28 Oct 2020

Do Natural Killer Cells Hold the Key to Treating Blood Cancers?

Novel immunotherapies, like T cell therapy, may have shown recent successes but they also come with a number of setbacks, such as long timelines and serious adverse reactions. As CEO of the Dutch biotech Kiadis Pharma, Arthur Lahr has been leading the development of a technology that could overcome these limitations by using natural killer […]

October 28, 2020 - 7 minutesmins - By Larissa Warneck-Silvestrin

Interview 28 Sep 2020

From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah

Novartis’ Kymriah, one of the first CAR T-cell therapies to be approved to treat blood cancer, has revolutionized both oncology and gene therapy. Gaurav Shah, now CEO of Rocket Pharmaceuticals, led the team that developed it. Shah began his career as a clinician, but soon moved over into the biotech sector to work at ImClone, […]

September 28, 2020 - 9 minutesmins - By Helen Albert

News and Trends 14 Sep 2020

T-Cell Therapy Firm Wins Massive €93M Series A to Treat Solid Tumors

The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a spectacularly large Series A round in Europe this year. The Series A round was co-led by the VC firms EcoR1 Capital, Syncona, and Jeito Capital. Neogene Therapeutics will use part of the €93M proceeds to advance its T-cell therapy immuno-oncology […]

September 14, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 11 Aug 2020

How European Startups Have Advanced Cancer T-Cell Therapy in 2020

With the help of a huge €66M Series A round last week, the German startup T-knife is developing cancer T-cell immunotherapies with the help of genetically modified mice. However, this is just one of several cancer T-cell therapy startups making advances this year, with other innovations including off-the-shelf treatments and a potential universal cancer therapy. […]

August 11, 2020 - 8 minutesmins - By Kostas Vavitsas

News and Trends 21 Jan 2020

T-Cell Discovery Could Herald Universal Cancer Immunotherapy

An international research team has found a new type of T-cell that could lead to cell immunotherapies able to treat cancers beyond the reach of current CAR T-cell therapies. Market-approved CAR T-cell therapies including Yescarta and Kymriah have revolutionized cancer treatment by modifying immune T-cells to hunt down cancer cells. However, these treatments are only […]

January 21, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 15 Jan 2020

Adaptimmune to Take Off-The-Shelf CAR-T to Phase I with Astellas

The UK biotech Adaptimmune Therapeutics has inked a deal worth up to €806M with Japanese Astellas Pharma to complete phase I trials of candidate off-the-shelf T-cell therapies for cancer including CAR T-cell and TCR therapies. According to the deal, Adaptimmune will collaborate with Universal Cells, a subsidiary of Astellas. The partners will aim to identify […]

January 15, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Jan 2020

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

Best in Biotech 30 Dec 2019

European Biotech’s Top News in 2019

With the year coming to a close, it’s time to review the most important biotech news events that took place in the European biotech industry in 2019. It has been a solid year for the European biotech industry. In 2019, venture capital funding in Europe continued to be high after a very good year in […]

December 30, 2019 - 10 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us